Pyxis Oncology Provides Corporate and Financial Update
March 29, 2022 06:35 ET
|
Pyxis Oncology
Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Developed IO Candidate Anti-KLRG1...
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
March 22, 2022 06:35 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to...
Pyxis to be Added to Russell 2000® Index
December 15, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat...
Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer
December 09, 2021 08:30 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will...
Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
November 15, 2021 07:15 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat...
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
November 10, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual...
Pyxis Announces Pricing of Upsized Initial Public Offering
October 07, 2021 22:24 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target...
Pyxis Oncology Appoints Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer
September 14, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s...
Pyxis Oncology Strengthens Board of Directors
September 08, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin...
Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer
August 31, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial...